Does Wegovy stop you feeling hungry — and how quickly?

How does Wegovy actually reduce the feeling of hunger?

Semaglutide is a synthetic version of GLP-1 (glucagon-like peptide-1), a hormone your gut releases naturally after eating. When Wegovy binds to GLP-1 receptors in the brain (particularly in the hypothalamus, the region that governs appetite) it reinforces the signals your body uses to decide it has had enough. At the same time, it slows how quickly the stomach empties into the small intestine, which means the physical sensation of fullness lingers well past the end of a meal.

The result for many people is not simply eating less at mealtimes but feeling less preoccupied with food generally. That persistent background pull (the mid-morning snack urge, the restlessness around 3pm) tends to soften. Some people describe it as the food noise finally turning down. If you want a detailed look at that specific experience, our page on whether Wegovy stops food noise goes into that further.

It is worth being clear: semaglutide does not block hunger entirely for everyone, and it is not intended to. The licensed goal is weight management alongside a reduced-calorie diet and increased activity, not the elimination of appetite. What the medicine does is make sticking to those lifestyle changes considerably more achievable for many people. The NHS semaglutide medicines page sets out the mechanism and common effects in accessible language.

When do you stop feeling hungry on Wegovy, what should you actually expect week by week?

This is one of the questions our prescribers hear most often. The honest answer is that the timeline varies, and the dose ladder matters a lot here.

Treatment starts at 0.25 mg weekly, a tolerability dose intended to let your body adjust rather than to produce the full therapeutic effect. At this stage, appetite changes are usually mild. As the dose steps up (to 0.5 mg, then 1.0 mg, 1.7 mg, and eventually 2.4 mg) most people find the hunger reduction becomes progressively more noticeable. For some, a meaningful shift happens within the first two to four weeks. For others, the clearer change arrives at the 1.0 mg or 1.7 mg step, sometimes eight to twelve weeks in. If you are wondering whether you should still feel hungry on Wegovy at all, the answer depends on your dose stage and how far into treatment you are. The STEP 1 trial ran for 68 weeks; weight loss (and by extension appetite suppression) continued to accumulate across that whole period, not just in the early weeks.

Our page on hunger on Wegovy looks at what happens if you are still feeling hungry partway through treatment, a common and manageable situation. For practical guidance on eating well while the medicine builds up, what to eat on Wegovy covers diet alongside treatment in detail.

One thing to set aside is the expectation of a clean on/off switch. Hunger tends to recede in layers, and that is normal.

Does semaglutide affect hunger differently at different doses?

Yes, and this is clinically important. The dose-response relationship for appetite suppression with semaglutide is fairly clear: higher doses tend to produce stronger appetite reduction, which is a primary reason the maintenance dose was set at 2.4 mg in the STEP trials. More recently, the MHRA approved a 7.2 mg dose (initially delivered as three 2.4 mg pens weekly and, from April 2026, as a single dedicated pen) which trials showed producing around 20.7% average weight loss over 72 weeks. Whether that approval translates to meaningfully stronger hunger suppression for a given individual is a question for the prescriber who knows your full picture.

If the question is specifically about whether semaglutide (the molecule behind Wegovy) is the right choice for you versus tirzepatide (the molecule behind Mounjaro, which acts on two gut-hormone receptors rather than one), that is a comparison worth exploring. Our weight-loss treatment overview covers both licensed options side by side, and how semaglutide affects hunger specifically goes deeper on the mechanism. The NICE appraisal of Wegovy (TA875) sets out the clinical evidence and the licensed population in the UK.

Cost is a reasonable thing to factor in when weighing options. Our page on Wegovy pricing in the UK sets the market context honestly, though for a prescription medicine, clinical fit and safe supply matter more than headline numbers.

What changes to expect beyond hunger, and when to talk to a prescriber

Reduced hunger is usually welcome, but the changes semaglutide brings are not all neutral. Nausea is the most common early side effect, it tends to be most noticeable in the first week or two after a new dose and settles for most people as the body adjusts. Vomiting, diarrhoea, constipation and indigestion also appear in the common side effects listed in the NHS semaglutide patient information. These are not reasons to stop without speaking to a prescriber first.

More important to flag: if your appetite drops so sharply that you are struggling to eat enough protein or keep yourself hydrated, that needs clinical attention rather than willpower. Severe, persistent stomach pain that radiates to the back (with or without vomiting) should prompt urgent medical help, as pancreatitis is a known (though infrequent) risk with GLP-1 medicines. The MHRA issued a specific safety communication on this in January 2026.

Your pen is delivered by DPD in plain, unbranded packaging, so there is nothing identifiable on the doorstep, but the more important box to open is the conversation with your prescriber when something feels off. At nume, our clinical team is reachable seven days a week for exactly this.

If you have questions about suitability or want to explore whether Wegovy is right for you, start your free consultation and a GPhC-registered prescriber will review your details the same day.